Skip to content

Rotator Cuff Augmentation With Human Dermal Allograft Versus Bovine Collagen Xenograft Patch: A Randomized Controlled Trial

Clinical and Cost Effectiveness of Rotator Cuff Augmentation With Human Dermal Allograft Versus Bovine Collagen Xenograft Patch: a Randomized Controlled Trial

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06215417
Acronym
HDA v Regen
Enrollment
102
Registered
2024-01-22
Start date
2024-03-31
Completion date
2029-12-31
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rotator Cuff Tears

Brief summary

Randomized controlled trial comparing human dermal allograft with bovine collagen xenograft in rotator cuff repair.

Detailed description

Randomized controlled trial comparing human dermal allograft with bovine collagen xenograft in rotator cuff repair. Subjects will be randomized intraoperatively after confirmation of inclusion criteria. Subjects will be followed-up at 3 weeks, 3 months, 6 months, 12 months and 24 months post-operatively. Primary outcome is Western Ontario Rotator Cuff Index (WORC) at 12 months. Additional outcomes include American Shoulder and Elbow Surgeons questionnaire (ASES), Single Numeric Evaluation (SANE) score, EuroQoL (5 domains) score (a quality of life score), and Visual Analogue Scale, healing rate as determined by Magnetic Resonance Imaging (MRI) scan at 12 months post surgery. To determine the cost utility, data will be collected on the cumulative cost for the total episode of care up to 12 months post surgery inclusive of surgical costs, implant costs, outpatient costs, and medication costs. Quality-Adjusted Life Years (QALYs) gained will be calculated using the mean total cost and the quality of life score (EQ-5D) improvement from pre-operative to 12 months post surgery.

Interventions

PROCEDURERotator cuff repair

Arthroscopic rotator cuff repair augmented with graft.

Sponsors

University of Calgary
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Patients and research assistants collecting data will be unaware of the treatment assigned until the completion of the study.

Intervention model description

This study is designed as a parallel group 1:1 randomized controlled trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

\>18 years \- fully reparable full thickness rotator cuff tear whereby the treating surgeon feels a graft augment is needed to enhance healing

Exclusion criteria

* tears where only a partial repair is achieved * significant glenohumeral joint arthropathy (Hamada grade 2 and above) * irreparable rotator cuff tears * patients unable or unwilling to consent or comply with study questionnaires * patients with upper limb neurological deficits affecting the ipsilateral limb * workers compensation cases * cases involving litigation

Design outcomes

Primary

MeasureTime frameDescription
Western Ontario Rotator Cuff Index (WORC)12 mos post-oprotator cuff quality of life outcome questionnaire

Secondary

MeasureTime frameDescription
Western Ontario Rotator Cuff Index (WORC)pre-op, 3 mos, 6 mos, 24 mos post-oprotator cuff quality of life outcome questionnaire
Single Assessment Numeric Evaluation (SANE)pre-op, 3mos, 6mos, 12mos, 24mos post-opnumeric score indicating shoulder assessment
EuroQOL5Dpre-op, 3mos, 6mos, 12mos, 24mos post-opgeneral health assessment score
Shoulder pain assessed by visual analog scale (VAS)pre-op, 3mos, 6mos, 12mos, 24mos post-opassessment of shoulder pain
Anatomic healing12mos post-opanatomic healing as assessed via MRI

Contacts

Primary ContactKristie More, MSc
kristie.more@ucalgary.ca14032208954

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026